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Abstract Although sudden cardiac death (SCD) is one of the
most important modes of death in Western countries, pathol-
ogists and public health physicians have not given this prob-
lem the attention it deserves. New methods of preventing po-
tentially fatal arrhythmias have been developed and the
accurate diagnosis of the causes of SCD is now of particular
importance. Pathologists are responsible for determining the
precise cause and mechanism of sudden death but there is still
considerable variation in the way in which they approach
this increasingly complex task. The Association for
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European Cardiovascular Pathology has developed these
guidelines, which represent the minimum standard that is re-
quired in the routine autopsy practice for the adequate inves-
tigation of SCD. The present version is an update of our orig-
inal article, published 10 years ago. This is necessary because
of our increased understanding of the genetics of cardiovas-
cular diseases, the availability of new diagnostic methods, and
the experience we have gained from the routine use of the
original guidelines. The updated guidelines include a detailed
protocol for the examination of the heart and recommenda-
tions for the selection of histological blocks and appropriate
material for toxicology, microbiology, biochemistry, and mo-
lecular investigation. Our recommendations apply to univer-
sity medical centers, regionals hospitals, and all healthcare
professionals practicing pathology and forensic medicine.
We believe that their adoption throughout Europe will im-
prove the standards of autopsy practice, allow meaningful
comparisons between different communities and regions,
and permit the identification of emerging patterns of diseases
causing SCD. Finally, we recommend the development of
regional multidisciplinary networks of cardiologists, geneti-
cists, and pathologists. Their role will be to facilitate the iden-
tification of index cases with a genetic basis, to screen appro-
priate family members, and ensure that appropriate preventive
strategies are implemented.
Keywords Autopsy . Guidelines . Protocol . Sudden cardiac
death
Introduction
The present document is an update of the 2008 Guidelines for
autopsy investigation of sudden cardiac death (SCD) devel-
oped by the Association for European Cardiovascular
Pathology (AECVP) [1]. The update is timely in light of the
new developments and increased availability of diagnostic
tools at post-mortem and the growing awareness that a signif-
icant proportion of SCD, particularly at young age, are due to
heredo-familial diseases. The writing committee is composed
of clinical and forensic pathologists whose collective interests
and experience cover the full range of disorders causing SCD.
An extensive literature surveywas conducted and all members
of the writing committee approved the guidelines.
Definitions and epidemiology
Sudden death (SD) is often the first clinical manifestation of an
underlying disease in previously asymptomatic, apparently
“healthy” subjects. In this setting, autopsy represents the first,
and only, opportunity to establish and register an accurate cause
of death. In recent decades, there has been a substantial worldwide
decrease in autopsy rates. As a result, important information may
not reach national health registries and essential investigations and
preventative care may not be implemented [2–4].
The major difficulties in interpreting epidemiological data are
the lack of standardization in death certificate coding and the
variability in the definition of SD and SCD. SCDhas been defined
as “a natural, unexpected fatal event occurring within one hour
from the onset of symptoms in an apparently healthy subject or in
one whose disease was not so severe as to predict an abrupt
outcome” [5]. This is a good description ofmanywitnessed deaths
in the community or emergency departments. It is less satisfactory
in pathological practice, especially forensic practice, where autop-
sies may be requested on patients whose deaths were not
witnessed, occurred during sleep, or at an unknown time before
their bodies were discovered. Under these circumstances, it is
probably reasonable to assume that death was sudden if the de-
ceasedwas known to be in good health 24 h before death occurred
[6]. Furthermore, for practical purposes, a death can also be clas-
sified as sudden if a patient was resuscitated after a cardiac arrest,
survived on life support for a limited period, and then died due to
irreversible brain damage.
Other definitions commonly used by cardiologists include
sudden arrhythmic death syndrome (SADS) when both autop-
sy and toxicology investigations are inconclusive, the heart is
structurally normal at gross and histological examination, and
non-cardiac etiologies are excluded (in infants it is called sud-
den infant death syndrome, SIDS). Sudden unexplained death
syndrome (SUDS) is used when death is without an apparent
cause and an autopsy has not been performed (in infants it is
called sudden unexplained death in infancy, SUDI) [7].
However, clear contradictions arise when comparing the
meaning of these terms with that accepted in common forensic
practice, where the death is considered as unexplained only by
exclusion, i.e., after adequate post-mortem investigation in-
cluding autopsy, death scene investigation, and the evaluation
of the medical history of the victim and his/her family and of
the circumstances of death.
Worldwide cardiovascular diseases are considered to be
responsible for approximately 17 million deaths every year
and about 25% are SCD [8]. A recent systematic review of
publications on the incidence of SCD in the USA demonstrat-
ed that very few studies used primary data, that is data collect-
ed directly from first-hand experience. In addition, definitions
of SCD and cardiac arrest are not standardized across the
medical community [9]. The incidence of SCD increases dra-
matically with age, in parallel with the age-related increase of
coronary heart disease. In adolescents and young adults
(<35 years), the approximate incidence is 0.01 per 1000 per
year and cardiomyopathies, myocarditis, premature coronary
artery disease, congenital coronary artery anomalies, and
channelopathies play a major causative role [10–12]. The in-
cidence of SCD then increases, reaching about 1 per 1000 per
year in the subjects 35–40 years, 2 per 1000 per year by
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60 years, and 200 per 1000 per year in the elderly [13, 14]. Of
course, the distribution of risk varies according to clinical and
population profiles. The overall estimate in the population is
in the range of 300,000–350,000 SCDs per year in the USA
[15, 16]. Event rates in Europe are similar to those in the USA
[17], but with significant geographic variations. The risk in-
creases in higher-risk subgroups. For instance, the SCD inci-
dence is 0.1–0.2 per 1000 per year in subjects with a high
coronary risk profile, 0.5 per 1000 per year in those with a
prior coronary event, 1.5 per 1000 per year in those with
congestive heart failure and ejection fraction (EF) < 35%,
and 2.5 per 1000 per year in cardiac arrest survivors. A com-
bination of prior myocardial infarction, low EF and ventricular
tachycardia, is associated with a SCD risk of nearly 3.5 per
1000 per year [18] . However, nearly two third of SCDs occur
as the first clinical manifestation of cardiac disease or, in the
setting of known cardiac disease, in the absence of risk
predictors.
Autopsies in SD cases
Pathologists are responsible for establishing the precise
cause of SD but there is considerable variation in the
way in which they approach this increasingly complex
task. A variety of book chapters, professional guidelines,
and articles have described how pathologists should in-
vestigate SD. However, there is little consistency between
centers, even in individual countries. We describe the
minimum standard that is required in the routine autopsy
practice for the adequate assessment of SCD in the gen-
eral population, excluding SIDS.
Autopsies in SD cases are generally performed in two
distinct settings, the clinical autopsy and the forensic au-
topsy. The clinical autopsy is performed at the request of
the physician of the deceased or even the family in some
countries depending on the national law. In cases of SD,
the goal of the clinical autopsy is to determine whether
death was due to cardiac disease or one of the many non-
cardiac causes. The clinical autopsy generally includes
histology. Despite important advances over the last
10 years, ancillary examinations, such as toxicology, mi-
crobiology, and sampling for genetics are, all too often,
not adequately performed. The forensic autopsy is per-
formed in the case of unexpected, unexplained, or alleged
unnatural deaths. A forensic autopsy may be requested by
a magistrate, public prosecutor, official death investigator,
coroner, or the police to assist in determining the cause
and manner of death. Considerable variations exist regard-
ing the legal aspects of authorization and consent in dif-
ferent countries, even though the norm for the harmoni-
zation of medico-legal autopsies was established by the
European Union in 1999 [19].
The role of the autopsy in SD
To establish or consider:
& whether death is attributable to a cardiac disease or to
other causes of SD;
& the nature of the cardiac disease, and whether the mecha-
nism was arrhythmic or mechanical;
& whether the condition causing SD may be inherited, re-
quiring screening and counseling of the next of kin
& the possibility of toxic or illicit drug abuse, trauma, and
other unnatural causes;
& the role of third persons in the death.
Clinical information relevant to the autopsy
In practice, the amount of information that is available before
autopsy is variable. Information from family members or the
general practitioner of the deceased can be especially valu-
able. Ideally, the following information is required:
& Age, gender, occupation, lifestyle (especially alcohol or
smoking), usual pattern of exercise or athletic activity;
& Circumstances of death: date, time interval (instanta-
neous or number of hours after onset of symptoms),
place of death (at home, at work, in hospital, at
recreation), circumstances (at rest, during sleep, dur-
ing exercise, and whether athletic or non-athletic,
during emotional stress), witnessed or un-witnessed,
any suspicious circumstances (immersion, traffic ac-
cident, intoxication, etc.);
& Past medical history: general health status, previous sig-
nificant illnesses (especially syncope, chest pain, and pal-
pitations, particularly during exercise, hypertension, respi-
ratory and recent infectious disease, epilepsy, asthma,
etc.), previous surgical operations or interventions, previ-
ous ECG tracings and chest X-rays, results of cardiovas-
cular examination, laboratory investigations (especially
lipid profiles); congenital deafness, periodic paralysis, cal-
cium and potassium metabolism alterations, or any other
relevant medical history, not related to the cardiovascular
system, that could raise the suspicion of a systemic disease
with cardiac involvement;
& Previous cardiovascular intervention: the pathologists
should discuss with the surgeon and interventional
cardiologist before, during, or after the autopsy.
The surgical and interventional report should be al-
ways obtained before the autopsy and/or heart
examination;
& Prescription and non-prescription medications;
& Family cardiac history: ischemic heart disease and prema-
ture SD, arrhythmias, inherited cardiovascular diseases,
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unexplained syncope, epilepsy, pacemaker or ICD (im-
plantable cardioverter defibrillator), heart transplant;
& ECG tracing taken during resuscitation, serum enzyme,
and troponin measurements.
The autopsy procedure
All SD autopsies should be sequential structured examina-
tions. They should specifically address the major causes of
extra-cardiac and cardiac SD. All aspects of the autopsy pro-
cedure should adhere to the Recommendations on the
Harmonisation of Medico-Legal Autopsy Rules produced by
the Committee of Ministers of the Council of Europe [19] .
External examination of the body
& Establish body weight and height (to correlate with heart
weight and wall thicknesses) [20–23].Measurement of the
waist circumference of the cadaver and calculation of the
so-called waist-to-height ratio has been also proposed
[24].
& Look for any dysmorphic feature, skin, hair, skeletal ab-
normalities, etc.
& At a forensic autopsy, all external and internal injuries are
studied and described in detail and are usually
photographed. In some departments, CT and MR imaging
are performed before post-mortem and this practice may
become more common.
& Check for recent intravenous access, intubation, ECG
pads, defibrillator and electrical burns, drain sites, and
traumatic lesions.
& Check for ICD/pacemaker [25]; see Medicines and
Healthcare products Regulatory Agency 2008 notice for
safe removal and interrogation [26].
Full autopsy, with sequential approach to the causes of SD
Exclusion of non-cardiac causes of natural SD
Any natural SD can be considered cardiac in origin after ex-
clusion of non-cardiac causes. Thus, a full autopsy with se-
quential approach should be always performed to exclude
common and uncommon extra-cardiac causes of SD,
especially:
& Cerebral (e.g., subarachnoid or intracerebral hemorrhage)
& Respiratory (e.g., asthma, bronchopneumonia)
& Acute hemorrhagic shock (e.g., ruptured extra-pericardial
aortic aneurysm, peptic ulcer)
& Septic shock (Waterhouse-Friderichsen syndrome)
Search for cardiac causes of SD
Many cardiovascular diseases can cause SCD, either through
an arrhythmic mechanism (electric SCD) or by compromising
the mechanical function of the heart and great vessels (me-
chanical SCD). These disorders may affect the coronary arter-
ies, the myocardium, the cardiac valves, the conducting sys-
tem, the intra-pericardial aorta, or the pulmonary artery.
The standard gross examination of the heart
1. Check the pericardium, open it, and explore the pericar-
dial cavity.
2. Check the anatomy of the great arteries and open the pul-
monary artery in situ to identify embolus, before
transecting them 3 cm above the aortic and pulmonary
valves.
3. If congenital heart disease is suspected, the heart and
lungs are best removed en bloc by cutting the pericardi-
um from the diaphragm and transecting the inferior vena
cava, aorta, and esophagus.
4. If aortic dissection is suspected, the continuity of the as-
cending aorta with aortic arch and descending thoraco-
abdominal aorta up to the iliac bifurcation should be
maintained.
5. Check and transect the pulmonary veins. Transect the
superior vena cava 2 cm above the point where the crest
of right atrial appendagemeets the superior vena cava (to
preserve sinus node). Transect the inferior vena cava
close to the diaphragm.
6. Open the right atrium from the inferior vena cava to the
apex of the appendage. Open the left atrium between the
superior pulmonary veins and then to the atrial append-
age. Inspect the atrial cavities and the inter-atrial septum
and determine whether the foramen ovale is patent.
Examine the mitral and tricuspid valves (or valve pros-
theses) from above and check the integrity of the papillary
muscles and chordae tendineae.
7. Inspect the aorta, the pulmonary artery, and the aortic
and pulmonary valves (or valve prosthesis) from above.
8. Check coronary arteries:
a) examine the size, shape, position, number, and paten-
cy of the coronary ostia (Fig. 1);
b) assess the size, course, and “dominance” of the major
epicardial arteries;
c) makemultiple transverse cuts at 3-mm intervals along
the course of the main epicardial arteries, including
branches such as the diagonal and obtuse marginal,
and check patency (Fig. 2a, b);
d) heavily calcified coronary arteries should be removed
intact, decalcified, and opened transversely;
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sometimes, they can be examined in situ with trans-
verse sections made with sharp scissors;
e) coronary artery segments containing a metallic stent
should be referred intact to laboratories with facilities
for resin embedding. This permits sectioning of the
arterial wall with the stent in situ, preserving their an-
atomic relationships [27]. In the early hours or days,
after implantation, stents can be opened longitudinally,
removed, and checked for thrombus. As an alternative,
a scalpel can be used to cut down onto the stented
vessel to inspect the stent lumen; thrombus filling the
lumen can be removed for standard histology.
Electrochemical and other novel techniques for disso-
lution of metallic and plastic stents that permit subse-
quent embedding of arteries in paraffin have been de-
scribed [28]. These allow thin sectioning, special stain-
ing, and immunohistochemistry and are currently un-
der investigation [29]. Radiology of the stented vessel
before any further study is recommended;
f) coronary artery bypass grafts (saphenous veins, inter-
nal mammary arteries, radial arteries, etc) should be
carefully examinedwith transverse cuts. The proximal
and distal anastomoses should be examined with par-
ticular care. Side branch clips or sutures may facilitate
their identification, particularly internal mammary
grafts.
9. Make a complete transverse (short-axis) cut of the heart
at the mid-ventricular level and then further parallel
transverse slices of ventricles at 1 cm intervals towards
the apex. Assess these slices carefully looking for chang-
es in the cut surface of the myocardium and the endo-
cardium of the ventricular cavities. (Fig. 3a, b). We
strongly recommend not to dissect the myocardium with
slices parallel to the endo-epicardial surfaces.
10. Triphenyltetrazolium (TTC) staining can be used in the
autopsy room for preliminary diagnosis of acute myo-
cardial infarction. A 1-cm thick ventricular slice should
be selected and immersed in neutral TTC solution for
15–20 min at 37 °C.
11. Once emptied of blood, the following measurements
should be always obtained:
a) Total heart weight: assess weight of heart against ta-
bles of normal weights by age, gender, and body
weight/height [20–23].
b) Wall thickness: carefully inspect the endocardium,
measure the thickness of mid-cavity free wall of the
left ventricle and right ventricle and the interventric-
ular septum (excluding trabeculae). Compare the
measurements against tables of normal thickness by
age, gender, and body weight [20–22]. Additional
measurements can be made to estimate of the dimen-
sions of chambers. Transverse size is best calculated
as the distance from the obtuse to the acute margin in
the posterior atrio-ventricular sulcus. The
RCA
LCA
Fig. 1 After a transection of the aorta 3 cm above the aortic valve,
inspection of the coronary ostia location in the proper sinus (LCA=left
coronary artery; RCA= right coronary artery)
Fig. 2 a Schematic
representation of serial cross
sectioning of the sub-epicardial
coronary artery tree. b A careful
inspection of the serial sections is
needed not to miss any coronary
lesion. A transverse cut of the first
tract of the left anterior
descending coronary artery
appears occluded by thrombosis.
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longitudinal size is obtained from a measurement of
the distance between the crux cordis (i.e., the point at
which the atrio-ventricular sulcus meets the posterior
interventricular sulcus) and the apex of the heart on
the posterior aspect.
12. Dissect the remainder of right and left ventricles in the
basal half of the heart in the direction of flow of blood.
Complete the examination of atrial and ventricular septa,
atrio-ventricular valves, ventricular inflows and out-
flows, and semilunar valves. If there is ECG evidence
of ventricular pre-excitation, the atrio-ventricular rings
should be maintained intact.
Referral of hearts to specialized centers
Best practice is that the entire heart is retained and sent to
a specialized center for an expert opinion [30]. The refer-
ring pathologist should complete steps 1–7, including
making a transverse apical section of the heart and emp-
tying the heart of blood. Tissues, blood, and other fluids
for additional testing should be taken before fixing the
heart in formalin (see below).
If the heart cannot be retained, it is essential that
extensive photographic documentation is made, indicating
where individual blocks are taken. At least one transverse
section of the heart including the left and right ventricle
should be retained for further examination.
Hearts from patients after surgery or percutaneous
interventions
Pathologists should be familiar with recent developments in
surgical and interventional treatment of cardiovascular dis-
eases. These include new generations of coronary stents, ab-
lation techniques, closure devices, and transcatheter valves,
some of which create “novel” pathology with an inherent risk
of SD. Discussion with the surgeon and/or interventional car-
diologist before, or even during the autopsy, is again therefore
of the utmost importance [31]. SD after surgery for complex
congenital heart disease, including grown-up congenital heart
disease, is an increasingly common event. The pathologist
must understand the specific nature of the congenital anomaly
involved and the exact operative procedures that were per-
formed. In cases of congenital heart diseases, the heart-lung
block should ideally be kept intact, fixed in formalin, and sent
to a specialized cardiac pathology service [30].
Examination of the heart can be very difficult when exten-
sive pericardial adhesions have developed after previous car-
diac surgery. Nevertheless, specimens should be handled care-
fully in order to prevent damage or dislodgment of prostheses,
stents, catheters, arterial conduits, and anastomoses or
vascular grafts. A plain X-ray of the heart including surround-
ing fibrous adhesions can be very helpful in the localization of
prosthetic devices. After coronary artery surgery, a post-
mortem angiogram to visualize the patency of grafts and their
run-off into distal native arteries could be helpful.
The standard histologic examination of the heart
& Myocardium: take mapped labeled blocks from a repre-
sentative transverse slice of the ventricles to include the
free wall of the left ventricle (anterior, lateral, and poste-
rior), the ventricular septum (anterior and posterior), and
the free wall of the right ventricle (anterior, lateral, and
posterior), as well as right ventricular outflow tract (Fig.
4a, b). Left ventricular myocardial sections should include
the papillary muscles. Additionally, one block from each
atria and any area with significant macroscopic abnormal-
ities should be taken. H & E and a connective tissue stain
(Elastic van Gieson, trichrome or Sirius red) are standard.
Other special stains and immunohistochemistry should be
performed as required.
& Coronary arteries: in the setting of coronary artery disease,
the most severe focal lesions should be sampled for his-
tology in labeled blocks and stained as above.
& Other cardiac samples (such as valvular tissue, pericardi-
um, and aorta) as indicated.
& If the clinical history or ECG tracing suggest an un-
usual conduction abnormality, the heart should be re-
ferred intact to a specialist center. The selection of
blocks for the histological assessment of the conduc-
tion system requires particular expertise and serial sec-
tions are usually required.
Other tissues for histological examination
Specimens from the major organs should be taken routinely
and stained with H & E and appropriate other stains.
Photographic documentation
Modern methods of digital photography and video recording
allow accurate documentation of normal and abnormal anatomy
[32]. They are an essential part of a forensic autopsy but are also
valuable innatural SD. InSCD, indefinite storageof entire hearts
is not feasible and inmanycountries, organ retention is subject to
either legal or ethical restriction. The written description of the
heart, along with detailed photographs, forms the permanent re-
cord of the case.Webelieve that any gross finding relevant to the
final diagnosis should be photographed and stored in the labora-
tory information system. This is of particular importance when
the heart cannot be retained.
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We recommend that photographs are taken before his-
tological blocks are dissected from the heart, that they
should contain an identification number and a ruled refer-
ence scale. Photographs should also be taken before any
cardiac device is removed. Finally, the sites of the sections
taken for histology should be photographed or described
in detail in the report. This may help in the correct inter-
pretation of the histological findings.
Post-mortem imaging
In cardiovascular deaths, traditional plain X-ray images and
post-mortem computed tomography (PMCT) are helpful in
visualizing hemopericardium, calcified plaques, and valves,
and in identifying and locating cardiovascular devices.
Angiographic methods provide detailed views of the distribu-
tion pattern of epicardial coronary arteries, information on
extent and location of arterial stenoses and obstructions, and
specifically, the patency of stents and bypass grafts [33, 34].
Plain X-ray image and coronary angiography practiced on
isolated hearts are easy and more accessible methods than
whole body imaging and additional post-mortem coronary
angiograms can be made immediately after removal of the
heart using a small cabinet system [33]. Whole body imaging
by PMCT and post-mortem magnetic resonance imaging
(PMMR), with or without angiography, are increasingly used,
especially in forensic practice. In addition, religious objections
to invasive autopsies have led to a demand for minimally
invasive radiological methods, with or without post-mortem
biopsy of selected organs. There are advantages and
a bFig. 3 Short axis cross sectioningof the heart specimen from mid-
ventricular to apical levels. a
gross view of the specimen before
cross sectioning. b transverse
sections of the heart at the three
different levels as represented in a
a b
Fig. 4 a Sampling of the myocardium with several transmural blocks, circumferentially along the left ventricle, septum and right ventricle. b An
additional sampling of the right ventricular outflow tract myocardium can be also taken
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disadvantages to different whole body imaging methods,
which are related to the logistics, costs, and image quality.
Some reports suggest that in natural deaths these methods
are less accurate than a standard autopsy, especially in cardio-
vascular deaths [35–38]. However, PMCT angiography does
allow the evaluation of vessels, including coronary arteries
[34, 39, 40]. PMMR is currently available in only a few aca-
demic centers.Myocardial abnormalities can be visualized but
the images may be modified by post-mortem changes in heart
muscle [41, 42]. At present, the AECVP task force does not
recommend the routine use of post-mortem imaging in the
investigation of SD, but recognizes the added value in specific
causes of death.
Further post-mortem laboratory tests
Additional laboratory analyses as toxicology, chemistry, mi-
crobiology, and genetic testing may be required at the time of
autopsy, or at a later stage. National and international recom-
mendations for forensic autopsy sampling and subsequent
analyses should be applied [see Table 1]. In the absence of
suitable on-site facilities, stored material should be sent to
specialized local or regional centers. National legal and ethical
aspects must be considered, in particular for post-mortem ge-
netic testing.
Toxicology
In all cases of SD, even if the heart is found to be ab-
normal at macroscopic and/or microscopic examination,
the possibility that an illicit drug or a prescribed drug
may have triggered the death, acting as additional factor
to the anatomical substrate, should be carefully considered
[43]. Many prescribed drugs or illicit substances have
acute or long-term cardiovascular toxicity [44, 45]. Some
prescribed drugs, such as antipsychotics, can modify the
QT intervals or provoke myocarditis. Genetic factors play
a role in the individual response to some medications and
gene–drug interaction should be considered, especially
with QT interval-acting drugs [46]. Illicit drugs, especially
cocaine, have well described acute and chronic effects on
the cardiovascular system [47–49]. However, many other
recreational drugs can be involved in SD and novel “de-
signer” drugs are continually appearing on the streets. As
some of these cannot be detected by routine assays, close
collaboration with toxicologists is necessary [50].
Chemistry
Post-mortem biochemistry is valuable in the diagnosis
of deaths due to metabolic disorders, including alcoholic
and diabetic ketoacidosis, electrolyte disorders, and ana-
phylaxis, when there is a prolonged stress responseTa
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(hypothermia, starvation), and might be useful in the
diagnosis of disease processes such as inflammation,
early myocardial infarction, and sepsis [51–53].
Microbiology
Myocarditis is a well-recognized cause of SCD, especially in
the young. The cause can be infective (mostly viral), toxic,
allergic, drug induced, or immune. In lymphocytic myocardi-
tis, molecular techniques such as polymerase chain reaction
(PCR) on both myocardial tissue and blood are the gold stan-
dard for the diagnosis of viral myocarditis [54, 55]. The viral
genome load should be quantified, particularly for viruses
such as PVB19, which is frequently present as an innocent
bystander [56]. Systemic sepsis and organ infection, including
endocarditis, are uncommon, but well-recognized causes of
SD. Cultures of blood, cerebrospinal fluid, spleen, or cardiac
vegetation should be considered [57].
Genetic testing
Many cardiovascular diseases causing SCD have a genetic back-
ground. Some are associated with well-defined structural abnor-
malities but in others, the heart may be macroscopically and
microscopically normal. The likelihood that a case of unex-
plained SCD is caused by an underlying inherited disorder has
led to the emerging role of genetic testing of DNA obtained at
autopsy (also called “molecular autopsy,” but the term post-
mortem genetic testing is preferable) [55, 58]. Thus, pathologists
play an important role in the identification of families at risk, by
reporting whether it is recommended to refer first-degree family
members for clinical screening and/or to perform additional post-
mortem genetic testing with cascade genetic screening, based
upon the autopsy findings [59–62]. In Table 2, diseases are listed
in whom cardiological assessment of relatives is recommended
according to international guidelines [58, 59, 63–75]. Only a
minority of these studies specifically gives recommendations
for genetic testing in the DNA of the deceased probands. In
particular, according to the ESC guidelines [7], targeted post-
mortem genetic analysis of potentially disease-causing genes
should be considered in all SD victims in whom a specific inher-
itable channelopathy or cardiomyopathy is suspected (Class of
recommendation IIa, level of evidence C). However, in most of
European countries, post-mortem genetic testing is performed
only if there is genetic counseling of family members. After
genetic counseling, it can be decided to perform genetic testing
of the deceased in the context of the family screening.
Formulation of a diagnosis and the clinico-pathological
summary
Theautopsyreportshouldconcludewithaclearclinico-pathological
summaryof themajor positive findings and their relationship to theTa
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cause of death (epicrisis). As far as possible, this should relate the
pathological findings to theclinical history, thecircumstancesof the
death, to any investigation performed close to the time of the death
and to the resultsof all laboratoryanalyses. In themajorityofSCDs,
a clear pathological cause can be identified, albeit with varying
degrees of confidence. When the morphological findings, and the
results of additional analyses, do not indicate a single specific diag-
nosis, the full range of possible differential diagnoses should be
discussed. These should be ranked in order of probability [76, 77]
andwhenever possible, themost likely underlying cause should be
stated [78].
It is important to accept that different degrees of certainty exist
in defining the cause-effect relationship between the cardiovas-
cular findings and the SD event. Table 3 lists the commonest
substrates of SCD, classifying each as certain, highly probable,
or uncertain. In the probable, and especially the uncertain cate-
gories, each case should be considered on its individual merits.
The clinical history, the circumstances of death, and the results of
ancillary analyses may influence the decision-making process.
Finally, there are myocardial diseases in which the border
between physiological and pathological changes is poorly de-
fined. Some of these diagnostic gray zones are described in
Table 4 [64, 79–81]. In everyday practice, pathologists should
make a detailedmacroscopic andmicroscopic description of their
findings, without implying a cause and effect relationship. If
there is real doubt as to whether the changes are physiological
or pathological, an expert opinion should be sought.
The clinical history, the autopsy findings, and the results of
all ancillary examinations must be considered together when
estimating the certainty of a cause of death. Interpretation of
results of toxicology can be difficult. Quantification of drug
levels, rather than their simple identification, is essential.
Specific expertise may be necessary to state whether the
amount of a particular drug is within the therapeutic range or
potentially or definitely toxic. The information obtained from
toxicological analyses depends not only on the presence of the
substance in the body but also on analytical methods used.
These include screening procedures, confirmation procedures,
and specific methods. Many analytical pitfalls, especially for
screening procedures by immunoassay, should be considered
[82]. Moreover, substantial changes can occur in blood drug
levels between the time of death and the autopsy. These
changes are not easily identifiable by post-mortem sampling
and toxicological analyses. They are related to drug degrada-
tion, neo-formation, artefactual formation, post-mortem redis-
tribution, and individual pharmacogenomics [46]. The inter-
pretation of post-mortem chemistry is limited by the lack of
knowledge on defined reference ranges in life, by the effects
of autolysis and other post-mortem changes and time interval
between death and sampling [51, 53].
Table 4 The gray zone between normal and/or secondary changes and pathologic changes of the myocardium
Changes in the range of normality
or secondary changes
Pathologic changes Comments
Fatty infiltration of the right
ventricular wall
Arrhythmogenic cardiomyopathy Massive fatty infiltration of the right ventricle, without any
evidence of replacement-type fibrosis and myocyte
degeneration, should not be considered a diagnostic finding
of arrhythmogenic cardiomyopathy, especially in obese, elderly
people and people with alcohol abuse
Exercise-induced left ventricular
hypertrophy (athlete’s heart)
Hypertrophic cardiomyopathy An enlarged left ventricular cavity with increased wall
thicknesses up to 13–14 mm is present in more than one
third of highly trained athletes. Detailed histology essential
Focal myocardial disarray
without hypertrophy
Hypertrophic cardiomyopathy
without hypertrophy
Macroscopic changes are not always present in hypertrophic
cardiomyopathy. Isolated myocardial disarray confined to the
antero-septal and postero-septal junctions should be
considered physiologic. For a confident diagnosis, additional
findings, such as interstitial and/or replacement fibrosis and
abnormal intramyocardial blood vessels should be
searched for
Scattered inflammatory foci with or
without small foci of fibrosis
Focal myocarditis In the absence of myocyte necrosis, small foci of inflammatory
cells (even after immunohistochemistry), are not sufficient
evidence of myocarditis. Scattered small foci of fibrosis are
also insignificant.
Circumferential, subendocardial
myocardial ischemia+/−
hemorrhage after resuscitative maneuvers
Regional or circumferential,
sub-endocardial
myocardial ischemia
without resuscitative maneuvers
Ischemic changes of the myocardium, particularly when
sub-endocardial and diffuse require exclusion of
prolonged resuscitative maneuvers
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Finally, there are deaths that remain unexplained after careful
macroscopic, microscopic, and laboratory analyses (referred as
SADS by the clinicians) [83–85]. We strongly suspect that the
numbers of these unexplained deaths have been underestimated
in the past and that there are many borderline cases. There is in-
creasing evidence that SCD in these instances might be due to
inherited ion channel disorders, which produce well-defined ab-
normalities in a basal or effort ECG. In this setting, the availability
of ECG tracings may be crucial for the diagnosis and molecular
studies are essential. First-degree relatives should be referred to a
department with specific expertise in inherited cardiac conditions
for clinical screening and, when indicated, subsequent genetic
analysis. High-throughput approaches, such as massive parallel
or next-generation sequencing, enable rapid analysis of many
genes at low cost and with a higher success rate than with Sanger
technology. In a SCDvictim, particularly in the absence of a clear
phenotype, the mere identification of a genetic defect is not suffi-
cient to establish a diagnosis and state the cause of death [86]. A
multidisciplinary approach is essential. Genetic information
shouldalwaysbe interpreted in theclinical contextof thedeceased
and his/her family and the autopsy findings [61, 87].
Conclusions
Autopsy represents the first and last opportunity tomake an accu-
ratediagnosis inSCD.Our recommendedmethodof investigation
hasbeenupdatedand includesnotonlyaprotocol for examination
of the heart and histological sampling, but, when necessary, for
toxicology,microbiology, biochemistry, andmolecular investiga-
tion. Our recommendations apply not only to university medical
centers and regional hospitals but also to all people practicing
pathology and forensic medicine. If these guidelines are adopted
throughout theEuropeanUnion, theywill lead to improvements in
standards of practice and will allow meaningful comparisons be-
tween different communities and regions.Most importantly, they
will facilitate the identification of novel causes, and emerging pat-
terns of diseases, causing SCD.
The writing committee strongly supports the establishment of
regional multidisciplinary expert networks. These should include
pathologists, cardiologists, and geneticists, working in collabora-
tionwithmicrobiologists, toxicologists, and radiologists. Thema-
jorpurposesofthesenetworksaretoimprovethediagnosisofSCD
and to identify andorganizepreventive strategies for familymem-
bers in the setting of genetic abnormalities.
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